Neurotech International Ltd. · ASX:NTI
Neurotech International — Corporate Update (September 2023)
19 slides from Neurotech International's corporate update, Sep 15, 2023
Slide 1: Clinician Briefing Presentation and Webcast (ASX Announcement)
ASX Announcement 15 September 2023 Clinician Briefing Presentation and Webcast Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today provides the investor pre
Slide 2: PANDAS/PANS Clinician Education Seminar – Professor Dale
For personal use only Improving Lives PANDAS/PANS Clinician Education Seminar – Professor Dale 15 September 2023
Slide 3: Today's Speaker
Dr Thomas Duthy Executive Director, Neurotech International Neurotech Today’s Speaker NTI164 Phase Q&A PANDAS/PANS I/II Clinical Trial Background Prof. Dale For personal use only 2
Slide 4: Disclaimer
Disclaimer IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that
Slide 5: Neurotech is a clinical-stage biopharmaceutical development company
Neurotech is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders For personal use only Novel oral NTI164 exclusive worldwide Patents Pending – biopharmaceutical licence for neurological Use, Composition cannabinoid platform disorders (NTI
Slide 6: Neurotech Four Core Strategies
Neurotech Four Core Strategies For personal use only Focus On Rare Focus on Paediatric Patients Neurological Disorders with Neuroinflammation Focus on Partnering with Focus On Drug Product Key Opinion Leaders / Development Clinicians 5
Slide 7: Clinical Pipeline – 2023
Clinical Pipeline – 2023 Pre-Clinical Phase I/II Phase II/III For personal use only NTI164 NTI164 NTI164 Combination Therapies Prednisone, Diclofenac, Other Cerebral Palsy ASD Other Licensed NTI164 Strains PANDAS / PANS Pipeline (2020/1) NTI164 ASD NTI164 Combination Therapies (54 week open label ex
Slide 8: Today's Speaker – Professor Russell Dale
Today’s Speaker – Professor Russell Dale • Professor of Paediatric Neurology, University of Sydney • Petre Professor of Paediatric Neurology Research Head, Kids Neuroscience Centre, Children's Hospital at Westmead • Academic Leader (Research), Specialty of Child and Adolescent Health, Faculty of Med
Slide 9: Professor Russell Dale
Professor Russell Dale For personal use only 8
Slide 10: About PANDAS / PANS
About PANDAS / PANS What is it? Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) – PANDAS is a subgroup of PANS For personal use only PANS and PANDAS are severe forms of obsessive-compulsive
Slide 11: About PANDAS / PANS: Key questions
About PANDAS / PANS Key questions PANDAS/PANS has generated some controversy The ‘clinical entity’ is not in question- some children present with infection For personal use only triggered acute onset OCD, eating restriction and separation anxiety The question is ‘what is it?’- routine investigations
Slide 12: Recognised Diagnostic & Treatment Guidelines
Recognised Diagnostic & Treatment Guidelines Diagnostic Criteria (2015) Treatment (2017) The PANS/PANDAS Research Consortium, in conjunction with the NIMH, The PANS/PANDAS Research Consortium, consisting over 30 experts and issued a consensus statement regarding diagnosing PANS/PANDAS in the the NIM
Slide 13: Selecting NTI164 for PANDAS/PANS
Selecting NTI164 for PANDAS/PANS • Preclinical and clinical studies to date have shown that NTI164 is a powerful neuro-anti-inflammatory modulator, can suppress a wide range of inflammatory cytokines, and improves neuronal cell viability • Neuroinflammation is hypothesised to be relevant to PANDAS/P
Slide 14: PANDAS/PANS Phase I/II Trial
PANDAS/PANS Phase I/II Trial “We encourage clinicians, teachers, providers, extended family, and friends to understand the human aspects of PANDAS/PANS as symptoms are often so distressing, causing high levels of caregiver burden. 1 For personal use only 1. https://aspire.care/what-is-pans/caregiver
Slide 15: NTI164 PANDAS/PANS Phase I/II - Trial
NTI164 PANDAS/PANS Phase I/II - Trial Enrolment • Open-label, patients must fulfil PANS criteria (n=15) • Primary Endpoints NTI164 Baseline • Revised Children’s Anxiety and Depression Scale-Parent-rated (RCADS-P) score For personal use only • Clinical Global Impression-Severity (CGI-S) • Clinical Gl
Slide 16: Genomic Analysis
Genomic Analysis • Powerful modern genomic analysis will provide evidence of molecular changes from baseline measures and after 12 weeks of treatment with NTI164 – first time ever collected in a prospective interventional trial in PANDAS/PANS For personal use only • Thesis is that PANDAS/PANS is an
Slide 17: Summary
Summary • Clinical program is progressing well into the extension phase • All patients have voluntarily elected to move to the extension phase of the trial to 52 weeks of treatment For personal use only • HREC approval to treat children who turned 18 during the treatment/extension phase • If positiv
Slide 18: Question and Answer Session
Question and Answer Session • To ask a question select ‘ask a question’ at the bottom of the Zoom meeting • To ask a question select ‘Chat’ Tab at the bottom of the Zoom meeting and type your For personal use only question and hit the Enter key • In the interest of time, some questions may be pooled
Slide 19: Contact Details
For personal use only Contact Details Dr Tom Duthy Executive Director [email protected] +61 402 493 727 *This presentation has been authorised by the Board of Neurotech International Limited www.neurotechinternational.com www.mentetech.com Neurotech International Limited (ASX: NTI) 18
Neurotech International — Corporate Update (September 2023) on 6ix